Revance Therapeutics Inc (RVNC)
3.515
+0.22
(+6.84%)
USD |
NASDAQ |
Apr 26, 10:57
Revance Therapeutics Revenue (TTM): 234.04M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 234.04M |
September 30, 2023 | 214.16M |
June 30, 2023 | 186.40M |
March 31, 2023 | 156.64M |
December 31, 2022 | 132.56M |
September 30, 2022 | 108.59M |
June 30, 2022 | 99.32M |
March 31, 2022 | 89.76M |
December 31, 2021 | 77.80M |
September 30, 2021 | 62.98M |
June 30, 2021 | 47.07M |
March 31, 2021 | 28.57M |
December 31, 2020 | 15.32M |
September 30, 2020 | 4.281M |
June 30, 2020 | 0.492M |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | 3.813M |
December 31, 2018 | 3.728M |
Date | Value |
---|---|
September 30, 2018 | 3.278M |
June 30, 2018 | 0.991M |
March 31, 2018 | 0.38M |
December 31, 2017 | 0.262M |
September 30, 2017 | 0.30M |
June 30, 2017 | 0.30M |
March 31, 2017 | 0.30M |
December 31, 2016 | 0.30M |
September 30, 2016 | 0.30M |
June 30, 2016 | 0.30M |
March 31, 2016 | 0.30M |
December 31, 2015 | 0.30M |
September 30, 2015 | 0.30M |
June 30, 2015 | 0.30M |
March 31, 2015 | 0.30M |
December 31, 2014 | 0.383M |
September 30, 2014 | 0.617M |
June 30, 2014 | 0.70M |
March 31, 2014 | 0.70M |
December 31, 2013 | 0.617M |
September 30, 2013 | 0.425M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.492M
Minimum
Jun 2020
234.04M
Maximum
Dec 2023
97.20M
Average
89.76M
Median
Mar 2022
Revenue (TTM) Benchmarks
AbbVie Inc | 54.32B |
Alnylam Pharmaceuticals Inc | 1.828B |
Ionis Pharmaceuticals Inc | 787.65M |
Madrigal Pharmaceuticals Inc | -- |
Vertex Pharmaceuticals Inc | 9.869B |